VIS-410
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- VIS-410
- immunoglobulin g1 anti influenza hemagglutinin human monoclonal vis410 gamma 1 chain disulfide with human monoclonal vis410 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
- vis 410
- Vis-410
- vis410
- Vis410
- VIS410
- CAS registry numbers
- 2043950-09-8
- ChEMBL ID
- CHEMBL4594613
- FDA ingredient codes (UNII)
- 14WE3Z92C4
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Hemagglutinin inhibitor
- Action type
- Inhibitor
- Target
- Hemagglutinin
- Protein identifier
- B4URE7
Open Targets mechanisms
- Mechanism
- Hemagglutinin inhibitor
- Action type
- Inhibitor
- Target
- Hemagglutinin
Investigated indications
- Condition
- Influenza, Human
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
Open Targets indications
- Condition identifier
- EFO_0007328
- Highest recorded phase
- 2
- NCT02045472
- NCT02468115
- NCT02989194
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Study of VIS410 to Assess Safety and Pharmacokinetics
- Influenza Challenge Study of VIS410 in Healthy Volunteers
- Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
- Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
In development for (1)
- Influenza Phase 2